EMvision Medical Devices Ltd. (AU:EMV) has released an update.
EMVision Medical Devices Ltd has completed recruitment for its ‘EMView’ multi-centre pre-validation trial, enrolling over 300 participants, with Stage 3 results expected in November. The company unveiled its transformative, ultra-lightweight First Responder brain scanner, designed for rapid stroke diagnosis, and is progressing towards a road and air study. With a strong cash reserve and support from non-dilutive funding, EMVision is well-positioned to advance its innovative neurodiagnostic technology.
For further insights into AU:EMV stock, check out TipRanks’ Stock Analysis page.